These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 24900213)
21. Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series. Cox JM; Chu HD; Yang C; Shen HC; Wu Z; Balsells J; Crespo A; Brown P; Zamlynny B; Wiltsie J; Clemas J; Gibson J; Contino L; Lisnock J; Zhou G; Garcia-Calvo M; Bateman T; Xu L; Tong X; Crook M; Sinclair P Bioorg Med Chem Lett; 2014 Apr; 24(7):1681-4. PubMed ID: 24630411 [TBL] [Abstract][Full Text] [Related]
22. Discovery of Novel Seven-Membered Prostacyclin Analogues as Potent and Selective Prostaglandin FP and EP3 Dual Agonists. Sugimoto I; Kambe T; Okino T; Obitsu T; Ohta N; Nishiyama T; Kinoshita A; Fujimoto T; Egashira H; Yamane S; Shuto S; Tani K; Maruyama T ACS Med Chem Lett; 2017 Jan; 8(1):107-112. PubMed ID: 28105284 [TBL] [Abstract][Full Text] [Related]
23. Identification of N-phenyl-3-methoxy-4-pyridinones as orally bioavailable H Zhang M; Tang L; Jiang L; Wei J; Hu Y; Sheng R Eur J Med Chem; 2021 Feb; 212():113096. PubMed ID: 33395621 [TBL] [Abstract][Full Text] [Related]
24. Modulation of bladder function by prostaglandin EP3 receptors in the central nervous system. Su X; Leon LA; Wu CW; Morrow DM; Jaworski JP; Hieble JP; Lashinger ES; Jin J; Edwards RM; Laping NJ Am J Physiol Renal Physiol; 2008 Oct; 295(4):F984-94. PubMed ID: 18632791 [TBL] [Abstract][Full Text] [Related]
25. 3-Amido-3-aryl-piperidines: A Novel Class of Potent, Selective, and Orally Active GlyT1 Inhibitors. Pinard E; Alberati D; Alvarez-Sanchez R; Brom V; Burner S; Fischer H; Hauser N; Kolczewski S; Lengyel J; Mory R; Saladin C; Schulz-Gasch T; Stalder H ACS Med Chem Lett; 2014 Apr; 5(4):428-33. PubMed ID: 24900853 [TBL] [Abstract][Full Text] [Related]
26. The discovery of potent, selective, and orally bioavailable hNK1 antagonists derived from pyrrolidine. Lin P; Chang L; Devita RJ; Young JR; Eid R; Tong X; Zheng S; Ball RG; Tsou NN; Chicchi GG; Kurtz MM; Tsao KL; Wheeldon A; Carlson EJ; Eng W; Burns HD; Hargreaves RJ; Mills SG Bioorg Med Chem Lett; 2007 Sep; 17(18):5191-8. PubMed ID: 17637506 [TBL] [Abstract][Full Text] [Related]
27. Novel Potent Selective Orally Active S1P5 Receptor Antagonists. Ma B; Guckian KM; Liu XG; Yang C; Li B; Scannevin R; Mingueneau M; Drouillard A; Walzer T ACS Med Chem Lett; 2021 Mar; 12(3):351-355. PubMed ID: 33738061 [TBL] [Abstract][Full Text] [Related]
29. Novel nonpeptide CCK-B antagonists: design and development of quinazolinone derivatives as potent, selective, and orally active CCK-B antagonists. Padia JK; Field M; Hinton J; Meecham K; Pablo J; Pinnock R; Roth BD; Singh L; Suman-Chauhan N; Trivedi BK; Webdale L J Med Chem; 1998 Mar; 41(7):1042-9. PubMed ID: 9544204 [TBL] [Abstract][Full Text] [Related]
31. Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists. Riechers H; Albrecht HP; Amberg W; Baumann E; Bernard H; Böhm HJ; Klinge D; Kling A; Müller S; Raschack M; Unger L; Walker N; Wernet W J Med Chem; 1996 May; 39(11):2123-8. PubMed ID: 8667356 [TBL] [Abstract][Full Text] [Related]
32. Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors. Barlaam B; Cadogan E; Campbell A; Colclough N; Dishington A; Durant S; Goldberg K; Hassall LA; Hughes GD; MacFaul PA; McGuire TM; Pass M; Patel A; Pearson S; Petersen J; Pike KG; Robb G; Stratton N; Xin G; Zhai B ACS Med Chem Lett; 2018 Aug; 9(8):809-814. PubMed ID: 30128072 [TBL] [Abstract][Full Text] [Related]
33. Discovery of chiral dihydropyridopyrimidinones as potent, selective and orally bioavailable inhibitors of AKT. Parthasarathy S; Henry K; Pei H; Clayton J; Rempala M; Johns D; De Frutos O; Garcia P; Mateos C; Pleite S; Wang Y; Stout S; Condon B; Ashok S; Lu Z; Ehlhardt W; Raub T; Lai M; Geeganage S; Burkholder TP Bioorg Med Chem Lett; 2018 Jun; 28(10):1887-1891. PubMed ID: 29655979 [TBL] [Abstract][Full Text] [Related]
34. Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors. Yin Y; Zheng K; Eid N; Howard S; Jeong JH; Yi F; Guo J; Park CM; Bibian M; Wu W; Hernandez P; Park H; Wu Y; Luo JL; LoGrasso PV; Feng Y J Med Chem; 2015 Feb; 58(4):1846-61. PubMed ID: 25621531 [TBL] [Abstract][Full Text] [Related]
35. Novel selective, potent naphthyl TRPM8 antagonists identified through a combined ligand- and structure-based virtual screening approach. Beccari AR; Gemei M; Lo Monte M; Menegatti N; Fanton M; Pedretti A; Bovolenta S; Nucci C; Molteni A; Rossignoli A; Brandolini L; Taddei A; Za L; Liberati C; Vistoli G Sci Rep; 2017 Sep; 7(1):10999. PubMed ID: 28887460 [TBL] [Abstract][Full Text] [Related]
36. Discovery of a novel, potent and orally active series of gamma-lactams as selective NK1 antagonists. Paliwal S; Reichard GA; Shah S; Wrobleski ML; Wang C; Stengone C; Tsui HC; Xiao D; Duffy RA; Lachowicz JE; Nomeir AA; Varty GB; Shih NY Bioorg Med Chem Lett; 2008 Jul; 18(14):4168-71. PubMed ID: 18547807 [TBL] [Abstract][Full Text] [Related]
37. Identification of a novel 2-pyridyl-benzensulfonamide derivative, RQ-00203078, as a selective and orally active TRPM8 antagonist. Ohmi M; Shishido Y; Inoue T; Ando K; Fujiuchi A; Yamada A; Watanabe S; Kawamura K Bioorg Med Chem Lett; 2014 Dec; 24(23):5364-8. PubMed ID: 25455182 [TBL] [Abstract][Full Text] [Related]